Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $9.60.

A number of equities analysts have weighed in on the company. Wall Street Zen upgraded Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 26th. HC Wainwright upgraded Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $4.00 to $12.00 in a research note on Tuesday, July 29th. Royal Bank Of Canada upped their target price on Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a “sector perform” rating in a research note on Wednesday, July 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday.

Fulcrum Therapeutics Stock Down 6.5%

Shares of NASDAQ FULC opened at $8.99 on Friday. The firm has a market capitalization of $486.27 million, a P/E ratio of -7.37 and a beta of 2.93. The stock’s 50-day simple moving average is $7.45 and its two-hundred day simple moving average is $6.32. Fulcrum Therapeutics has a twelve month low of $2.32 and a twelve month high of $9.88.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. As a group, research analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Fulcrum Therapeutics

Several institutional investors have recently bought and sold shares of FULC. Jump Financial LLC purchased a new stake in Fulcrum Therapeutics during the 1st quarter valued at about $30,000. Brooklyn Investment Group boosted its holdings in Fulcrum Therapeutics by 209.7% during the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock valued at $35,000 after acquiring an additional 8,254 shares during the period. Virtu Financial LLC purchased a new stake in Fulcrum Therapeutics during the 1st quarter valued at about $39,000. Russell Investments Group Ltd. boosted its holdings in Fulcrum Therapeutics by 4,209.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after acquiring an additional 9,092 shares during the period. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in Fulcrum Therapeutics by 26.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock valued at $89,000 after acquiring an additional 2,677 shares during the period. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.